Eupraxia Pharmaceuticals at H.C. Wainwright conference: focus on durability

On 14 September 2026, Eupraxia Pharmaceuticals (EPRX) presented at the H.C. Wainwright 28th Annual Global Investment Conference, emphasizing the potential of its lead program to revolutionize eosinophilic esophagitis (EoE) treatment. The biotech highlighted promising early clinical data and the vast market opportunity, but also flagged the risk of confirming these results in the upcoming placebo-controlled Phase IIb interim readout due in December.

With a market cap of $554 million, Eupraxia's shares have risen by 58% over the past year, trading at $8.04. The stock is deemed undervalued by InvestingPro analysis and listed on the platform's Most Undervalued list. Eupraxia's lead EoE program hinges on physician-administered delivery, once-a-year dosing potential, and a drug mechanism already validated for the disease.

Management anticipates the Phase IIb interim readout to provide a full picture of symptom, biopsy, and safety data, potentially changing investors' perceptions of efficacy compared to DUPIXENT, provided the therapy offers similar results with superior durability and compliance.

Eupraxia's Phase IIa data demonstrated zero oropharyngeal candidiasis, no cortisol suppression, and over 3,000 injections completed without complications. EoE is considered more widespread by the company than many investors realize, potentially affecting 1 million patients in the U.S. by the time of launch in 2030. Currently, only one drug is approved for long-term chronic EoE use, capturing only 7% to 8% of the market.

Eupraxia's strategy centers on three key aspects: physician-administered delivery for compliance, potential once-a-year dosing, and a proven drug mechanism through off-label use.

The presentation focused on clinical development, market access, and commercial positioning, with no financial results, revenue figures, or balance-sheet updates discussed. Eupraxia's Phase IIb study is 95% recruited, with interim data expected in December. Approximately 90 patients will be assessed at three months (about three-quarters of the trial population), 45 at nine months, and 20 to 25 at one year.

Safety findings, histology, and symptom data from multiple endpoints will be shared in the December update, including the first placebo-controlled comparison.